Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis

Neurodegenerative Diseases

Volumn 5, Issue 1, 2007, Pages 32-37

  Taoufik, E ^a   Tseveleki, V ^a   Euagelidou, M ^a   Emmanouil, M ^a   Voulgari Kokota, A ^a   Haralambous, S ^a   Probert, L ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

Central nervous system; Multiple sclerosis; Tumor necrosis factor neutralization

Indexed keywords

INFLIXIMAB; LENERCEPT; NEUROPROTECTIVE AGENT; TUMOR NECROSIS FACTOR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; CONFUSION; GLIA CELL; HUMAN; MACROPHAGE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; WALKING DIFFICULTY;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; LEUKOCYTES; MULTIPLE SCLEROSIS; MYELIN SHEATH; TUMOR NECROSIS FACTOR-ALPHA; WALLERIAN DEGENERATION;

EID: 37149027558     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000109936     Document Type: Review

References (62)

1. Brosnan CF, Raine CS: Mechanisms of immune injury in multiple sclerosis. Brain Pathol 1996;6:243-257.
2. Ruuls SR, Sedgwick JD: Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis. Immunol Cell Biol 1998;76:65-73.
3. Lock C, Oksenberg J, Steinman L: The role of TNFα and lymphotoxin in demyelinating disease. Ann Rheum Dis 1999;58(suppl 1):I121-I128.
4. Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
5. Yang L, Lindholm K, Konishi Y, Li R, Shen Y: Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci 2002;22:3025-3032.
6. Munoz-Fernandez MA, Fresno M: The role of tumour necrosis factor, interleukin 6, interferon-γ and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol 1998;56:307-340.
7. Stoll G, Jander S, Schroeter M: Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 2002;513:87-113.
8. Merrill JE: Effects of interleukin-1 and tumor necrosis factor-α on astrocytes, microglia, oligodendrocytes, and glial precursors in vitro. Dev Neurosci 1991;13:130-137.
9. Cheng B, Christakos S, Mattson MP: Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 1994;12:139-153.
10. Chao CC, Hu S: Tumor necrosis factor-α potentiates glutamate neurotoxicity in human fetal brain cell cultures. Dev Neurosci 1994;16:172-179.
11. Selmaj K, Raine CS, Farooq M, Norton WT, Brosnan CF: Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J Immunol 1991;147:1522-1529.
12. Hisahara S, Shoji S, Okano H, Miura M: ICE/ CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. J Neurochem 1997;69:10-20.
13. Selmaj KW, Raine CS: Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23:339-346.
14. Hofman FM, Hinton DR, Johnson K, Merrill JE: Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989;170:607-612.
15. Cannella B, Raine CS: The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435.
16. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al: Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
17. Sharief MK, Hentges R: Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-472.
18. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA: Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 1990;40:1735-1739.
19. Fernandez-Arquero M, Arroyo R, Rubio A, Martin C, Vigil P, Conejero L, et al: Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis. Neurology 1999;53:1361-1363.
20. Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, et al: TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997;72:149-153.
21. Jurewicz A, Matysiak M, Tybor K, Kilianek L, Raine CS, Selmaj K: Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor. Brain 2005;128:2675-2688.
22. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, et al: An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990;172:1193-1200.
23. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M: Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994;24:2040-2048.
24. Frei K, Eugster HP, Bopst M, Constantinescu CS, Lavi E, Fontana A: Tumor necrosis factor α and lymphotoxin α are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med 1997;185:2177-2182.
25. Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD: Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 1997;186:1585-1590.
26. Kassiotis G, Pasparakis M, Kollias G, Probert L: TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur J Immunol 1999;29:774-780.
27. Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD: Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 1997;186:1585-1590.
28. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, et al: TNF is a potent antiinflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4:78-83.
29. Probert L, Akassoglou K: Glial expression of tumor necrosis factor in transgenic animals: how do these models reflect the 'normal situation'? Glia 2001;36:212-219.
30. Kassiotis G, Bauer J, Akassoglou K, Lassmann H, Kollias G, Probert L: A tumor necrosis factor-induced model of human primary demyelinating diseases develops in immunodeficient mice. Eur J Immunol 1999;29:912-917.
31. Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G, et al: Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 1998;153:801-813.
32. Taupin V, Renno T, Bourbonniere L, Peterson AC, Rodriguez M, Owens T: Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-α in the central nervous system. Eur J Immunol 1997;27:905-913.
33. Akassoglou K, Douni E, Bauer J, Lassmann H, Kollias G, Probert L: Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice. Proc Natl Acad Sci USA 2003;100:709-714.
34. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, et al: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-1534.
35. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group: TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-465.
36. Sicotte NL, Voskuhl RR: Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-1888.
37. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, et al: Effects of tumor necrosis factor-α on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69:1847-1855.
38. Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J: Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockers. Neurology 2005;64:1468-1470.
39. Botchkina GI, Meistrell ME III, Botchkina IL, Tracey KJ: Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol Med 1997;3:765-781.
40. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391-397.
41. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, et al: Tumor necrosis factor-α. A mediator of focal ischemic brain injury. Stroke 1997;28:1233-1244.
42. Dawson DA, Martin D, Hallenbeck JM: Inhibition of tumor necrosis factor-α reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett 1996;218:41-44.
43. Nawashiro H, Martin D, Hallenbeck JM: Inhibition of tumor necrosis factor and amelioration of brain infarction in mice. J Cereb Blood Flow Metab 1997;17:229-232.
44. Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, et al: Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996;2:788-794.
45. Hallenbeck JM: The many faces of tumor necrosis factor in stroke. Nat Med 2002;8:1363-1368.
46. Furukawa K, Mattson MP: The transcription factor NF-κB mediates increases in calcium currents and decreases in NMDA- and AMPA/kainate-induced currents induced by tumor necrosis factor-α in hippocampal neurons. J Neurochem 1998;70:1876-1886.
47. Gary DS, Bruce-Keller AJ, Kindy MS, Mattson MP: Ischemic and excitotoxic brain injury is enhanced in mice lacking the p55 tumor necrosis factor receptor. J Cereb Blood Flow Metab 1998;18:1283-1287.
48. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U: Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002;22:RC216.
49. Taoufik E, Valable S, Muller GJ, Roberts ML, Vivoux D, Tinel A, Voulgari-Kokota A, Tseveleki V, Altruda F, Lassmann H, Petit E, Probert L: FLIPL protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death. J Neurosci 2007;27:6633-6646.
50. Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S: High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 1994;78:399-408.
51. Lafaille JJ, Keere FV, Hsu AL, Baron JL, Haas W, Raine CS, et al: Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997;186:307-312.
52. Kohm AP, Carpentier PA, Anger HA, Miller SD: Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002;169:4712-4716.
53. Montero E, Nussbaum G, Kaye JF, Perez R, Lage A, Ben Nun A, et al: Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies. J Autoimmun 2004;23:1-7.
54. Jack C, Ruffini F, Bar-Or A, Antel JP: Microglia and multiple sclerosis. J Neurosci Res 2005;81:363-373.
55. Schwartz M, Shaked I, Fisher J, Mizrahi T, Schori H: Protective autoimmunity against the enemy within: fighting glutamate toxicity. Trends Neurosci 2003;26:297-302.
56. Shaked I, Porat Z, Gersner R, Kipnis J, Schwartz M: Early activation of microglia as antigen-presenting cells correlates with T cell-mediated protection and repair of the injured central nervous system. J Neuroimmunol 2004;146:84-93.
57. Butovsky O, Landa G, Kunis G, Ziv Y, Avidan H, Greenberg N, et al: Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis. J Clin Invest 2006;116:905-915.
58. Ziv Y, Ron N, Butovsky O, Landa G, Sudai E, Greenberg N, et al: Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci 2006;9:268-275.
59. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP: TNF-α promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001;4:1116-1122.
60. Heldmann U, Thored P, Claasen JH, Arvidsson A, Kokaia Z, Lindvall O: TNF-α antibody infusion impairs survival of stroke-generated neuroblasts in adult rat brain. Exp Neurol 2005;196:204-208.
61. Iosif RE, Ekdahl CT, Ahlenius H, Pronk CJ, Bonde S, Kokaia Z, et al: Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 2006;26:9703-9712.
62. Scherbel U, Raghupathi R, Nakamura M, Saatman KE, Trojanowski JQ, Neugebauer E, et al: Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci USA 1999;96:8721-8726.